ThermoGenesis launches cell processing system for cell therapies

By The Science Advisory Board staff writers

February 3, 2021 -- ThermoGenesis has completed the development process for its PXP-Lavare system for automated cell processing. The company has submitted a letter to file and updated the device listing with the U.S. Food and Drug Administration (FDA).

PXP-Lavare is a good manufacturing practice (GMP) compliant system that allows for fast, automated, and reliable washing and reformation of cell suspension. Its optional cell reformation accessory is designed for use with the PXP-1000 system, an FDA-cleared medical device that is used for downstream current GMP-compliant clinical manufacturing of cell-based therapeutics.

The completed closed system includes the control module, docking station, disposable cartridge, and DataTRAK software, which captures sample processing data to assist with quality assurance and compliance with current GMP practices.

ThermoGenesis launches new cell processing products
ThermoGenesis has started distribution of the X-Series cell processing platform under the Corning Life Sciences brand, as part of an exclusive global...
ThermoGenesis to develop COVID-19 therapeutics
ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics...

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter